co-transporter-2 (SGLT2)
INTRODUCTION
Healthy individuals are able to maintain tight glucose homeostasis by closely regulating glucose production, reabsorption, and utilization. The importance of this homeostatic mechanism is evident from the fact that, in spite of extreme variations in glucose intake, relatively few people develop either diabetes or hypoglycemia [1] .
In people without diabetes, about 180 g of glucose is filtered daily by the renal glomeruli, and is then reabsorbed in the proximal convoluted tubule (PCT). This is achieved by passive transporters, namely, facilitated glucose transporters (GLUTs), and active cotransporters, namely, sodium-glucose cotransporters (SGLTs). There are six identified SGLTs, of which two (SGLT1 and SGLT2) are considered most important [1] . These SGLTs are described in Table 1 [2] .
This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors (SGLT2i), and their clinical pharmacology, including mechanism of action and posology, and discusses the pragmatic placement of these molecules in the existing oral anti-diabetic drug arena. The article is based Electronic supplementary material The online version of this article (doi:10.1007/s13300-014-0089-4) contains supplementary material, which is available to authorized users. on previously conducted studies, and does not involve any new studies of human or animal subjects performed by the author.
HISTORY
The first SGLT2i discovered was phlorizin, a naturally occurring compound derived from apple tree bark. Because of its non-selective nature, it caused severe gastrointestinal symptoms. Due to this and to its poor oral bioavailability, work on its development could not continue [3] . Drugs which specifically inhibit SGLT2, and thereby avoid gastrointestinal effects related to SGLT1 inhibition, have now been developed, some of which are listed in Table 2 .
RATIONALE Glucosuria (i.e., the excretion of glucose through the kidneys) only occurs if the maximal capacity of various glucose transporter proteins (350 mg glucose/min) is exceeded [2, 4] . Earlier, glucosuria was thought to be a pathological mechanism, or a marker of illness. However, one may approach this condition from a different view point. Persons with ambient hyperglycemia are at risk of endothelial dysfunction and resultant complications, due to the high levels of glucose in circulation. Kidneys try to prevent an excessive rise in blood glucose levels by glucuresis, thereby mitigating the adverse effects associated with high glucose levels.
Theoretically, compounds which promote glucuresis should help to reduce circulating PCT proximal convoluted tubule, SGLT sodium-glucose co-transporter, SGLT2i sodium-glucose co-transporter-2 inhibitors Ipragliflozin Japan
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MECHANISM OF ACTION
Sodium-glucose co-transporter-2 inhibitors work by inhibiting SGLT2 in the PCT, to prevent reabsorption of glucose and facilitate its excretion in urine. As glucose is excreted, its plasma levels fall leading to an improvement in all glycemic parameters [4] [5] [6] . This mechanism of action is dependent on blood glucose levels and, unlike the actions of thiazolidinediones (mediated through GLUTs), is independent of the actions of insulin. Thus, there is minimal potential for hypoglycemia, and no risk of overstimulation or fatigue of the beta cells [7] . Because their mode of action relies upon normal renal glomerular-tubular function, SGLT2i efficacy is reduced in persons with renal impairment.
CLINICAL PHARMACOLOGY
Dapagliflozin is rapidly absorbed after oral administration, reaching peak plasma concentration in 2 h, and exhibiting oral bioavailability of 78% [8] . Dapagliflozin is metabolized by uridine diphosphateglucuronosyltransferase (UGT)1A9 in both the liver and kidneys [8] . Canagliflozin achieves maximal plasma concentration 1-2 h after oral administration (oral bioavailability 65%) and steady state after 4-5 days. It is metabolized by glucuronidation by UGT1A9 and UGT2B4 [9] . Table 3 .
Dapagliflozin and canagliflozin have proven efficacy in improving glycemic parameters, both as monotherapy and in combination [11] .
A 52-week comparison between canagliflozin 100 and 300 mg showed noninferiority, and canagliflozin 300 mg showed statistical superiority to sitagliptin in lowering glycated hemoglobin (HbA1c) [12] .
Canagliflozin 100 mg and 300 mg reduced bodyweight versus placebo at week 26 and sitagliptin at week 52. The published results are summarized in Table 4 . Four-year (208week) use of dapagliflozin with metformin produced a sustained and durable reduction in blood glucose levels with significantly less frequent adverse reactions as compared to glimepiride with metformin. After 4 years, the difference in HbA1c reduction between two groups was -0.3% [95% confidence interval (CI) -0.51, -0.09]. The trend over a period of time showed further increase in the difference with more prolonged use [13] .
The long-term efficacy and safety of empagliflozin have also been investigated as add-on therapy to basal insulin. Patients with type 2 diabetes mellitus (T2DM) were randomized to receive empagliflozin 10 or 25 mg once daily or placebo; the basal insulin regimen was kept constant for the first 18 weeks, after which the treating investigator could adjust the regimen at their discretion for the following 60 weeks [14] . As well as significant improvements in HbA1c, patients in both of the empagliflozin groups had significant reductions in their insulin doses at
week 78, and also registered weight loss versus a small weight gain in those receiving placebo [14] . The decrease in insulin requirements in patients on dapagliflozin has been evaluated in a study on insulin-mediated whole-body glucose uptake and endogenous glucose production using euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment for 2 weeks increased insulin-mediated tissue glucose disposal by 18% and resulted in an increase in endogenous glucose production (with increased fasting glucagon levels) [15] .
PLEIOTROPIC EFFECTS
Sodium-glucose co-transporter-2 inhibitors use leads to a reduction in body weight, ranging from about 1 to 5 kg [16] . A greater fall is seen in patients with long-standing diabetes and in those with a higher baseline weight. This weight loss is sustained after up to 2 years of use of dapagliflozin, and may be linked to a reduction in insulin dose requirements of patients with long-standing diabetes [16] .
Analysis
of 208-week data comparing dapagliflozin in combination with metformin versus glimepiride in combination with metformin showed 4.38 kg (95% CI -5.31, -3.46) difference between two groups. Patients in the glimepiride group gained a mean of 0.73 kg while those in dapagliflozin group lost 3.65 kg [13] .
While it may be argued that weight loss is because of volume depletion, it has been shown that two-thirds of the decreased weight is lost from fat mass (especially visceral abnormal fat), as compared to lean mass [14] . An initially rapid [20] . Analysis of 208-week data comparing dapagliflozin in combination with metformin versus glimepiride with metformin showed an increase of 0.2 mmHg (95% CI -1.66, 1.61) in the glimepiride group while those on dapagliflozin showed a reduction of 3.69 mmHg (95% CI -5.24, -2.14) [13] . Sodium-glucose co-transporter-2 inhibitors are either lipid-friendly or lipid-neutral drugs.
Canagliflozin, for example, increases highdensity lipoprotein (HDL) by 7.1-10.6%, lowdensity lipoprotein (LDL) by 7.1%, and reduces triglycerides by 2.3% [21, 22] . Treatment with canagliflozin for 104 weeks was also associated with increases in HDL-C and LDL-C, which is consistent with findings at week 52. However, the proportion of patients who started or modified therapy with lipid-modifying agents were 13%, 11.5%, and 13.3% in the canagliflozin 100 mg, canagliflozin 300 mg, [29] . Canagliflozin has a two-stage dosage regime.
The starting dose approved is 100 mg once daily, before the first meal of the day. In those who do not respond adequately, the dose can be increased to 300 mg, provided renal function is normal [10] .
Empagliflozin is being studied in daily doses of 10 and 25 mg. Trials have revealed dosedependent HbA1c reductions with empagliflozin monotherapy, which are greater as compared to those observed with sitagliptin, but similar to those experienced with metformin. Empagliflozin can be administered without relation to meal timings, in a oncedaily frequency [30] .
Ipragliflozin has Japanese approval for the treatment of T2DM, either alone or in combination with metformin, pioglitazone, SU, a-glucosidase inhibitor, DPP-4 inhibitor, or with nateglinide [30] .
ADVERSE EVENTS
The incidence of adverse events in clinical trials of SGLT2i is similar to that observed with other anti-diabetic drugs. The overall incidence of adverse events has ranged from 57.3 to 83.0%, while that of serious adverse events have varied between 1.0% and 12.6% [31] .
Uro-genital tract infections are the most frequently noticed adverse events in subjects on SGLT2i [32] , especially in women and in uncircumcised men. Pooled data from 12 placebo-controlled clinical trials of dapagliflozin reveal that when used in dose 2.5, 5, and 10 mg per day, the incidence of clinically diagnosed uro-genital tract infection was 4.1%, 5.7% and 4.8%, respectively, while it was 0.9% in the placebo group [33] . Common infections include vulvitis and vulvo-vaginitis in women, as well as balanitis and balanoposthitis in men. These can be prevented by maintaining adequate perineal hygiene, and through treatment with antifungal therapy. Genital infections are thought to be caused by an increased glucose load in the urinary tract, which encourages fungal growth. The incidence of urinary tract infections does not increase with SGLT2i therapy [34] .
The osmotic diuresis associated with SGLT2i use also has the potential to cause volume depletion and orthostatic hypotension. In randomized-controlled trials, however, the incidence of these adverse events has been minimal (\3%) [25] . All such events have been mild to moderate in severity. The extra diuresis experienced per day is 350-450 ml (one extra void per day) [34] , and does not cause nocturia.
The diuresis seen with SGLT2i may result in slight transient increase in serum creatinine and blood urea, with a corresponding fall in glomerular filtration rate (GFR). The risk of hypoglycemia is minimal with SGLT2i, as they have a non-insulin-based mechanism of action. However, hypoglycemia may occur when these molecules are used in complication with other anti-diabetic drugs, including metformin. Four-year comparison between dapagliflozin plus metformin and glipizide plus metformin showed a tenfold decrease in the incidence of hypoglycemic episodes (5.4% and 51.5%, respectively) [13] .
In this 208-week study, patients treated with dapagliflozin plus metformin had 35 hypoglycemic events as compared to 1, 191 events in glipizide plus metformin group. Dose-down titration during first year was required in 2.7% patients in the dapagliflozintreated group compared with 15.8% in the glipizide-treated group. This finding is very significant in light of the long-term consequences of hypoglycemic episodes on the physiology of patients and their compliance to treatment.
Sodium-glucose co-transporter-2 inhibitors use leads to a slight reduction in bone formation, and a rise in bone resorption markers, although there are no major changes on bone mineral density. A 102-week study with dapagliflozin did not identify any changes in markers of bone turnover as compared to placebo when added to metformin [27] . Other long-term studies have not demonstrated any significant increase in adverse drug reactions related with skeletal system with any of the SGLT2i [35, 36] .
USE IN RENAL IMPAIRMENT
In patients with reduced GFR, the amount of glucose reaching the PCT falls and the efficacy of SGLT2 may be suboptimal. Canagliflozin is prescribed in a full dose of 300 mg daily if GFR is above 60 ml/min and as 100 mg once daily if GFR is 45-60 ml/min [10] . Dapagliflozin can be prescribed as 5 or 10 mg once daily, depending upon the regulatory label in the country concerned [29] . A pooled analysis of 13 clinical trials exploring the long-term renal safety of dapagliflozin 10 mg as compared to placebo or other oral hypoglycemic agents showed no change in renal functions over a period varying from 12 to 104 weeks [25] .
Similarly, empagliflozin is being studied in doses of 10 and 25 mg per day [37] . [10] .
DRUG-DRUG INTERACTIONS
UGT enzyme-inducing agents increase the metabolism of canagliflozin thus leading to a decrease in peak plasma levels and reduced efficacy [32] . in insulin requirement of 0.79% and 0.39%, respectively [38] . Additionally, there was a significant decrease in insulin dose required by patients treated with dapagliflozin as compared to an increase in placebo group. A statistically significant decrease in body weight of up to 2.4 kg in the dapagliflozin 10 mg group as compared to an increase of 0.43 kg in the placebo group was also seen [38] .
CLINICAL USE
The ability to prescribe SGLT2i to persons with renal [39] and hepatic impairment, an easy two-step or one-step dose titration, a lack of relevant drug-drug interactions, and safety in combination with all routinely used CV and anti-diabetic drugs, are all points which will encourage their use.
Counseling regarding potential side effects and ways to prevent them, for example, perineal hygiene and avoidance of volume depletion, must accompany SGLT2i prescription.
A recent pilot study explored the potential role of SGLT2i in managing hyperglycemia associated with type 1 diabetes mellitus (T1DM) [40] . This 2-week exploratory study of dapagliflozin in doses ranging from 1 to 10 mg per day in addition to insulin, established its safety and pharmacokinetics, and explored the pharmacodynamics of a new class of drug for managing T1DM. Glucosuria increased by 88 mg/day in the dapagliflozin group while it decreased by 21.5 mg/day in the placebo group.
Additionally, a fall of 16.2% in the dapagliflozin group and an increase of 1.7% in the placebo group for total daily insulin dose were seen during this period [40] . More proof-of-concept studies are available documenting renoprotection provided by these agents in T1DM. Renal hyperfiltration which is an early hemodynamic abnormality preceding frank nephropathy in T1DM was improved with short-term use of these agents [41, 42] . Newer SGLT2i, still in pre-clinical and clinical phases of development, are expected to have a safer profile in view of their highly selective action [43, 44] .
CONCLUSION
The SGLT2i represent a novel class of drugs which will certainly help a large number of people with diabetes achieve target control in a safe and well-tolerated manner. Their unique mechanism of action, coupled with pleiotropic benefits on weight and blood pressure, should make them attractive choices for add-on therapy to persons not controlled on other medications.
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